But, she added, if her research goes forward, many will be able to participate in it. Obviously, like any additional study, it must be replicated and individually confirmed. Sam Gandy of the Mount Sinai Alzheimer’s Disease Research Center in New York said. Laurie Ryan, program director for Alzheimer’s disease scientific trials at the National Institute on Ageing, one of the National Institutes of Health, which funded the study.. Robert E. Schoen, M.D., M.P.H., Paul F. Pinsky, Ph.D., Joel L. Weissfeld, M.D., M.P.H., Lance A. Yokochi, M.D., M.P.H., Timothy Church, Ph.D., Adeyinka O. Laiyemo, M.D., M.P.H., Robert Bresalier, M.D., Gerald L. Andriole, M.D., Saundra S. Buys, M.D., E. David Crawford, M.D., Mona N. Fouad, M.D., Claudine Isaacs, M.D., Christine C. Johnson, M.D., Ph.D., M.P.H., Douglas J. Reding, M.D., M.P.H., Barbara O’Brien, M.P.H., Danielle M.The business has a quite strong track record in the regulatory filings with 150 US DMFs and over 2000 ANDA filings. Aurobindo’s evolution right into a key participant in the pharmaceutical industry originates from various beneficial factors such as cost competitive developing, operational excellence, diversified product portfolio and global leadership in anti-infective products.. AARP: Price of brand name drugs rose 9.7 percent last year ‘The AARP says that manufacturer prices for brand-name prescription medications commonly used by people on Medicare rose 9. ‘The cost of specialty medications like biologics and injectables rose 9.2 percent.